Clinical Trial Update: Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating subcutaneous methylnaltrexone for opioid-induced constipation in cancer patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Opioid-induced Constipation

Drugs mentioned

• Methylnaltrexone (methylnaltrexone)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Opioid-Induced Constipation | Phase 4 | Status: WITHDRAWN